BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IBI363 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IBI363\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122687-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:IBI363: Phase 2 readout est. (NCT07122687)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 C
 ombined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as N
 eoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081907-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:IBI363: Phase 1/2 readout est. (NCT06081907)
DESCRIPTION:IBI363\, phase 1/2.\nStudy: The Efficacy and Safety of IBI363 i
 n Solid Tumors\nEstimated primary completion: 1 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06081907
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05460767-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 1 readout est. (NCT05460767)
DESCRIPTION:IBI363\, phase 1.\nStudy: Safety\, Tolerability and Preliminary
  Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05460767
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402070-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT07402070)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 a
 s Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07402070
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797297-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT06797297)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study to Evaluate the Efficacy and 
 Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Un
 resectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Ha
 d Not Previously Received Systemic Therapy\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibi
 363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06797297
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289048-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:IBI363: Phase 2 readout est. (NCT07289048)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Prospective\, Single-Arm\, Explorat
 ory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07289048
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07342725-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:IBI363: Phase 1/2 readout est. (NCT07342725)
DESCRIPTION:IBI363\, phase 1/2.\nStudy: Phase Ib/II Study to Evaluate the S
 afety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Li
 ne Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Canc
 er\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07342725
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07408635-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:IBI363: Phase 2 readout est. (NCT07408635)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 (
 PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy 
 in Initially Unresectable Stage III Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 6 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ibi363#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07408635
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361991-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:IBI363: Phase 1/2 readout est. (NCT07361991)
DESCRIPTION:IBI363\, phase 1/2.\nStudy: IBI363 Plus Bevacizumab With or Wit
 hout Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer\n
 Estimated primary completion: September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07361991
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081920-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20281019
DTEND;VALUE=DATE:20281020
SUMMARY:IBI363: Phase 2 readout est. (NCT06081920)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study of IBI363 in Subjects With Ad
 vanced Melanoma\nEstimated primary completion: 19 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06081920
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IBI363: Phase 3 readout est. (NCT07722494)
DESCRIPTION:IBI363\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combined W
 ith Bevacizumab for Advanced Colorectal Cancer\nEstimated primary completi
 on: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ibi363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07722494
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217301-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:IBI363: Phase 3 readout est. (NCT07217301)
DESCRIPTION:IBI363\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
 \nEstimated primary completion: 1 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07217301
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307053-2254@assetmemo.bio
DTSTAMP:20261121T004516Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:IBI363: Phase 1/2 readout est. (NCT07307053)
DESCRIPTION:IBI363\, phase 1/2.\nStudy: Rare Tumor Focused Platform Study o
 f Innovative Therapies and Technologies (PLATFORM2)\nEstimated primary com
 pletion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibi363#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07307053
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
